key: cord-0793769-aeh4sd7k authors: Peng, Qian-Yi; Ma, Xin-Hua; Liu, Zhi-Yong; Zhao, Chun-Guang; Zhang, Lei; Qian, Zhao-Xin; Zhang, Li-Na title: Differences in clinical characteristics between younger and older patients with COVID-19 and their relationship with the length of hospital stay date: 2021-05-28 journal: nan DOI: 10.1016/j.jointm.2021.05.002 sha: b6e54c82c2423be97f8d0535d80728c85262f113 doc_id: 793769 cord_uid: aeh4sd7k Background : The coronavirus disease 2019 (COVID-19) pandemic is currently threatening the health of individuals worldwide. We compared the clinical characteristics between younger patients (aged <60 years) and older patients (aged ≥60 years) with COVID-19, detected the risk factors associated with a prolonged hospital stay, and examined the treatments commonly used with a particular focus on antiviral therapies. Methods : This retrospective study was conducted at the West Campus, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China). The sample consisted of 123 patients admitted to the hospital between February 9, 2020, and March 3, 2020. The data related to the demographics, laboratory findings, and treatment were analyzed to identify discrepancies between younger and older patients and those with and without primary diseases. The risk factors that contribute to a prolonged hospital stay were subsequently identified. Results : Patients aged ≥60 years required longer hospital stay than younger patients (P = 0.021 and P = 0.001, respectively). The percentage of lymphocytes was significantly lower in older patients and those with primary diseases (P = 0.016 and P = 0.042, respectively). The findings revealed that the risk factors that contributed to the length of hospital stay were age, the number of days of illness before hospitalization, white blood cell (WBC) count and albumin levels at admission, a neutrophil fraction at discharge, and antibiotic treatment. Analysis using a model that consisted of the above five risk factors for predicting prolonged hospital stay (i.e., >14 days) yielded an area under the ROC (AuROC) curve of 0.716. Antiviral and antibiotic treatments were administered to 97.6% and 39.0% of patients, respectively. The antiviral drugs most commonly administered were traditional Chinese medicine (83.7%) and arbidol (75.6%). Conclusions : In this study, older patients and those with primary diseases were at a higher risk of worse clinical manifestations. The physicians who treat the patients should pay close attention to the risk factors that contribute to the length of hospital stay, which could be used for predicting prolonged hospital stay. Traditional Chinese medicine and arbidol were the most frequently used antiviral drugs. Nevertheless, the extent to which these medications can effectively treat COVID-19 warrants further investigation. In December 2019, a novel coronavirus disease, which termed as coronavirus disease 2019 (COVID- 19) , was detected in Wuhan, China. It rapidly spread worldwide and was formally declared as a pandemic by the World Health Organization on March 11, 2020 . In some cases, COVID-19 can cause progressive lung injury that leads to respiratory failure, followed by circulatory instability, and multiple organ dysfunctions. [1] Previous investigations of population groups who are at risk of mortality and morbidity due to COVID-19 have consistently found that a large proportion of patients who are hospitalized have primary diseases and comorbidities (e.g., hypertension, diabetes, cardiovascular disease, and respiratory diseases). [1, 2] The risk factors associated with in-hospital death include older age, high Sequential Organ Failure Assessment score, history of smoking, markedly elevated body temperature at admission, respiratory failure, albumin, C-reactive protein (CRP), and D-dimer levels >1 µg/L. [3] [4] [5] However, the characteristics of critical COVID-19 infection according to the age of older patients remain unclear. Recently, a study by Liu et al [6] compared the characteristics of severe COVID-19 infection between young, middle-aged, and older patients. The evidence revealed that older patients who are considered as critical patients showed decreased high-sensitivity CRP and higher pro-brain natriuretic peptide levels. These fluctuations were independent risk factors for admission to the intensive care unit. However, the researchers did not compare the characteristics of patients with and without primary diseases, laboratory findings between admission and discharge, and treatment strategies. Moreover, there is a need to identify the risk factors that contribute to a prolonged hospital stay. This study aimed to further investigate the clinical differences between younger patients (aged <60 years) and older patients (aged ≥60 years) with COVID-19, as well as those with and without primary diseases, at the time of admission and discharge. The objective of this investigation was to detect the risk factors associated with prolonged hospital stay and to examine the commonly used treatments, with a particular focus on antiviral therapies. This retrospective study was approved by the Institutional Ethics Board of Xiangya Hospital, Central South University (Changsha, China) (approval number: 202003049). Owing to the retrospective nature of this research, the requirement for informed consent was waived. Patients with confirmed COVID-19 who were admitted to the West Campus, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, between February 9, 2020, and March 3, 2020, were included. Of note, patients without complete medical records were excluded. COVID-19 was diagnosed according to the interim guidance provided by the World Health Organization. [7] Data collection Demographic, clinical, laboratory, treatment, and outcome data were extracted from the electronic medical records of confirmed COVID-19 cases. For the purpose of accuracy, two researchers also independently reviewed the data collection forms. Primary diseases (e.g., hypertension, diabetes, coronary heart disease, nervous system disease, chronic kidney disease, malignant tumor, chronic obstructive lung disease, and other diseases) were determined from the past medical history of patients. Routine blood examination data consisted of complete blood count, coagulation profile, renal and liver function, electrolytes, myocardial enzymes, interleukin-6 (IL-6), CRP, and procalcitonin levels were also collected. All inpatients underwent examination through computed tomography (CT). The frequency of examinations was determined by the treating physician. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected by the local Centers for Disease Control and Prevention, local health institutions, Jingyintan Hospital (Wuhan, China), and Wuhan Pulmonary Hospital (Wuhan, China). The criteria for discharge were the absence of fever for ≥3 days, clinical remission of respiratory symptoms, substantial improvement in both lungs shown on chest CT, and two throat-swab samples negative for SARS-CoV-2 RNA obtained every 48 h. Continuous variables were presented as the mean ± standard deviation and compared using Student's independent t-test (for normally distributed data); homogeneity of variance was also detected. For non-normally distributed data, the Mann-Whitney U test was used. Categorical variables were reported as numbers and percentages and compared using the χ² test. A two-tailed P-value <0.050 considered statistically significant differences. The risk factors associated with the length of hospital stay were assessed by multivariate logistic regression using a forward-stepwise analysis. The results were summarized by estimating odds ratios (ORs) and respective 95% confidence intervals (CIs). All statistical analyses were performed using the SPSS Version 19.0 for Windows (IBM Corporation, Armonk, NY, USA) software. During the study, 137 patients were admitted to the West Campus of Union Hospital; of those, 14 patients were excluded due to incomplete medical data. Finally, 123 patients were included in this study [ Figure 1 ]. The mean age of the patients was 61.9 ± 12.07 years (range: 32-93 years); the majority of patients were males (56.9%; 70/123). The percentage of patients who had primary diseases was 61.8% (76/123); the most common primary diseases were hypertension (n = 42, 34.1%), diabetes (n = 32, 26.0%), coronary heart disease (n = 15, 12.2%), nervous system disease (n = 9, 7.3%), chronic kidney disease (n = 6, 4.9%), malignant tumor (n = 6, 4.9%), chronic obstructive lung disease (n = 4, 3.3%), and others (n = 286, 15.7%). The mean number of days of illness before hospitalization was 15.1 ± 9.34 days, and the mean length of hospital stay was 23.1 ± 10.97 days. The overall 28-day mortality rate was 4.1% (5/123) [ Table 1 ]. We compared the differences between the patients aged <60 years and ≥60 years, who were admitted to the hospital with COVID-19. The analysis revealed that the number of days of illness before hospitalization was significantly higher and the length of hospital stay was significantly longer (P = 0.021 and P = 0.001, respectively) in the latter group than in the former group. At admission, the lymphocyte count was considerably lower in the older patients (P = 0.040). In contrast, troponin I and myoglobin levels were significantly higher in older patients (P = 0.001 and P = 0.019, respectively). In addition, the coagulation index activated partial thromboplastin time (APTT) was significantly longer (P = 0.024), and the liver function index total bilirubin and renal function index blood urea nitrogen (BUN) were substantially higher (P = 0.008 and P = 0.035, respectively) in the older population. At discharge, the percentage of lymphocytes was also lower in older patients (P = 0.044), whereas the levels of direct bilirubin and BUN were significantly higher (P = 0.030 and P = 0.012, respectively) [ Table 1 ]. We also compared COVID-19 patients with and without primary diseases who were admitted to the hospital. The results revealed that the presence or absence of a primary disease did not have a significant influence on mortality and length of hospital stay. The mean age of patients with primary diseases was significantly higher than that of patients without primary diseases (P = 0.003). At admission, in patients with primary diseases, the percentage of lymphocytes and albumin levels were significantly lower (P = 0.042 and P = 0.016, respectively), whereas the levels of aspartate aminotransferase and creatinine were significantly higher (P = 0.045 and P = 0.035, respectively) [ Table 1 ]. Comparison of the laboratory findings revealed that the neutrophil fraction (N%) was significantly lower at discharge than at admission (P < 0.001). The platelet count and fibrinogen levels were also lower at discharge (P = 0.030 and P < 0.001, respectively). In contrast, procalcitonin was significantly higher at discharge (P = 0.028). Prothrombin time was significantly longer (P = 0.004) at discharge. The levels of albumin, direct bilirubin, and BUN were significantly higher at discharge (P < 0.001, P < 0.001, and P < 0.001, respectively) [ Table 2 ]. The treatment most often used in COVID-19 patients was antiviral treatment (97.6%), followed by antibiotic treatment (39.0%), glucocorticoids (13.8%), antifungal treatment (4.1%), and intravenous immunoglobulin therapy (1.6%). The use of glucocorticoids was more common in patients aged >60 years (P = 0.019). Among the antiviral treatments administered, the agents most often used were traditional Chinese medicine (83.7%, 103/123), arbidol (75.6%, 93/123), thymosin (62.6%, 77/123), ribavirin (51.2%, 63/123), lopinavir and ritonavir (23.6%, 29/123), and hydroxychloroquine (9.8%, 12/123). The most frequently prescribed glucocorticoids were intravenous methylprednisone (20-80 mg; daily once for 2-8 days) or oral prednisone (15-20 mg; daily once for 4-8 days). All patients were treated with oxygen therapy. The proportions of patients using high-flow nasal cannula oxygen therapy, non-invasive mechanical ventilation, and invasive mechanical ventilation were 4.9%, 4.1%, and 0.8%, respectively. Notably, these treatments were not associated with the length of hospital stay [ Table 1 ]. Risk factors associated with the length of hospital stay included age (P < 0.001, 95% Table 3 ]. The This retrospective study involved a cohort of 123 patients with severe laboratory-confirmed COVID-19 who required oxygen therapy. The present investigation focused on the differences in clinical characteristics between younger patients (aged <60 years) and older patients (aged ≥60 years) and those with and without primary diseases at the time of admission and discharge. The number of days of illness before hospitalization was higher and the length of hospital stay was longer in the present study than in previous studies. [3, 4, 8] These differences may be attributed to the relatively older age and more severe disease of patients admitted to the West Campus of Union Hospital. In this study, the in-hospital mortality rate was very low (4.1%). The findings revealed that older patients were ill for more days prior to hospitalization than younger patients, and the length of hospital stay was longer for older patients. We also analyzed in detail the differences in laboratory examination results between younger and older patients and those with and without primary diseases at the time of admission and discharge. According to a previous study, the age of 60 years was used as the cutoff value for the classification of middle-aged and older patients. [6] A reduction in the total number of lymphocytes was a clinical characteristic of COVID-19. [4, 7] A lymphocyte count <0.8 × 10 9 /L was associated with a higher risk of developing severe COVID-19. [8] We found that the percentage of lymphocytes was significantly lower in older patients and those with primary diseases, indicating a more severe inhibition of lymphocyte function in these groups. As the patients recovered, their lymphocyte counts increased and a significant decrease of N% at discharge was observed. Coagulation abnormalities (e.g., prothrombin time and APTT prolongation and hypercoagulability) were commonly detected among hospitalized patients with COVID-19. [9] In the present study, we found that APTT at admission was significantly longer in older patients. Abnormal liver and kidney functions were also more severe in older patients. Acute myocardial injury was common in patients with COVID-19 and associated with severity and adverse prognosis. [10, 11] In this study, we also found that the levels of troponin I and myoglobin were higher in older patients, indicating potential acute myocardial injury; however, acute myocardial infarction was not observed in our study. Previous studies have reported some risk factors associated with in-hospital death, including older age, high Sequential Organ Failure Assessment score, history of smoking, markedly elevated body temperature at admission, respiratory failure, albumin, CRP, and D-dimer levels >1 µg/L. [3, 5] Furthermore, patients aged >65 years are at a higher risk of developing symptoms that lead to critical illness or death. [2] In our study, the number of non-survivors was relatively small; hence, we did not investigate the risk factors associated with mortality but instead analyzed those linked to the length of hospital stay. As the mortality rate was very low, confounders such as rapid death of patients would not greatly influence the present results. The findings revealed that age, number of days of illness before hospitalization, WBC count and albumin levels at admission, N% at discharge, and antibiotic treatment were risk factors associated with the length of hospital stay. Previous studies have demonstrated that older age and albumin levels are important risk factors for mortality. [3, 5] This study indicated that these factors were also linked to a prolonged hospital stay. Routine blood test results are often the first laboratory results available to physicians who treat patients with COVID-19. In the early stages of COVID-19, normal or declined WBC counts as well as declined lymphocyte numbers can be observed in routine blood test results. [7] In the progressive stage of illness, WBC and neutrophil counts may increase in response to a secondary bacterial infection. Therefore, these cells are important markers of the severity of inflammation and the function of the immune system. Previous studies have reported that patients with severe COVID-19 had higher WBC and neutrophil counts and fewer lymphocytes. [9, 12] The findings of the present study demonstrated that WBC count at admission and N% at discharge were associated with the length of hospital stay. The use of antibiotics is often related to co-infection or secondary bacterial infection, which may lead to a prolonged hospital stay. We constructed a model consisting of five risk factors for predicting prolonged hospital stay (>14 days). The model yielded an AuROC of 0.716, indicating that these five risk factors may be combined to predict prolonged hospitalization. We chose 14 days as the cutoff value for the classification of normal or prolonged length of hospital stay. This selection was based on a systematic review which showed that the median length of hospital stay for patients with COVID-19 in China was 14 days. [13] In this study, antiviral treatment was administered to the vast majority of patients (97.6%). The most frequently used antiviral agents were traditional Chinese medicine (83.7%) and arbidol (75.6%). During the 2003 SARS epidemic, traditional Chinese medicine was found to exert a remarkable therapeutic effect. Therefore, it was also widely used in the fight against COVID-19 in China. The National Medical Products Administration listed COVID-19 as an additional indication for three Chinese patent medicines (i.e., Lianhua Qingwen capsule, Jinhua Qinggan capsule, and Xuebijing injection) and two herbal formulas (i.e., Qingfei Paidu decoction and Huashi Baidu decoction). [14, 15] Studies have shown that some traditional Chinese medicines [16] Studies have also reported that Lianhua Qingwen significantly inhibited the replication of SARS-CoV-2, affected the morphology of the virus, suppressed cytokine release, boosted immunity, and exerted antiviral and anti-inflammatory effects. [17] Previous studies [18, 19] have also reported that, in mild cases of COVID-19 treated with traditional Chinese medicine, the length of clinical symptoms, fever, and hospital stay were reduced by 2 days, 1.7 days, and 2.2 days, respectively. Furthermore, the improvement rate shown on CT images and clinical cure rate were increased by 22% and 33%, respectively, while the rate of progression to more severe illness was reduced by 27.4%. In severe cases treated with traditional Chinese medicine, the length of hospital stay and the time required to obtain a negative nucleic acid test were reduced by >2 days. [18, 19] These findings indicate that traditional Chinese medicine may be an effective adjuvant therapy for treating COVID-19 alongside Western medicine. The most frequently prescribed Western medication was arbidol, which has been linked to superior outcomes vs. lopinavir/ritonavir in the treatment of COVID-19. [20] Thymosin alpha-1 is also frequently prescribed. This agent acts through toll-like receptors in both myeloid and plasmacytoid dendritic cells, leading to the activation and stimulation of the immune response. [21] Therefore, the use of this drug may be beneficial for the treatment of immunosuppression status in the early stages of COVID-19. However, further studies are warranted to validate the effectiveness of these treatments. In this study, antibiotic and antifungal therapies were administered to 39.0% and 4.1% of patients, respectively. The most commonly used antibiotic agent was moxifloxacin. The antibiotic and antifungal treatments were primarily administered as a form of empiric therapy for the prevention of secondary infection. However, it should be noted that inappropriate use of antibiotics, particularly those that stimulate anti-inflammatory activity, may be associated with an inflammatory storm and septic shock in patients with COVID-19. [22] Glucocorticoidspredominantly used in patients with moderate-to-severe acute respiratory distress syndrome who require high-flow nasal cannula oxygen therapy, non-invasive, or invasive mechanical ventilationwere not frequently administered in this study (13.8%) . At present, the available evidence on the effectiveness of glucocorticoids in the treatment of patients with COVID-19 is relatively weak. Thus, further studies are required to develop a standardized protocol. Some physicians have recommended that doubling the usual dose of hydrocortisone for patients with mild COVID-19 symptoms may be an effective strategy for preserving the early activation of the immune response. In case of symptom deterioration, it is advisable to further increase the dose of hydrocortisone by up to 100 mg. For cases reaching a critical stage (e.g., rapid decrease in oxygenation) or experiencing an adrenal crisis, the management could involve treatment against refractory shock and the continuous intravenous administration of high doses (200 mg) of hydrocortisone. [23] To conclude, patients aged ≥60 years and those with primary diseases are at a higher risk of worse clinical manifestations. The risk factors that contributed to the length of hospital stay are age, the number of days of illness before hospitalization, WBC count and albumin levels at admission, N% at discharge, and antibiotic treatment; these factors could be used for predicting prolonged hospital stay. The most frequently prescribed antiviral drugs were traditional Chinese medicine and arbidol. Further studies are warranted to investigate the effects of these antiviral therapies on patients with COVID-19. None. This retrospective study was approved by the Institutional Ethics Board of Xiangya Hospital, Central South University (No. 202003049). Informed consent was waived due to the retrospective nature of this study. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: Interim guidance Review of the clinical characteristics of coronavirus disease 2019 (COVID-19) A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients Hematological findings and complications of COVID-19 Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan COVID-19 length of hospital stay: A systematic review and data synthesis Can we predict the severity of coronavirus disease 2019 with a routine blood test National Health Commission of the People's Republic of China. Guideline on diagnosis and treatment of COVID-19 Progress in the study of traditional Chinese medicine for the treatment of influenza Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Traditional Chinese medicine for COVID-19 treatment Press conference of the joint prevention and control mechanism of state council on Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 Immune modulation with thymosin alpha 1 treatment Possible cause of inflammatory storm and septic shock in patients diagnosed with (COVID-19) COVID-19 infection and glucocorticoids: Update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency Data are expressed as mean ± standard deviation, and median (first quartile AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CK: Creatine kinase; CK-MB: Creatine kinase isoenzyme-MB; Cr: Creatinine; CRP: C-reactive protein; CRRT: Continuous renal replacement therapy; DBil: Direct bilirubin; FiB: Fibrinogen; Hb: Hemoglobin; IL: Interleukin; LDH: Lactate dehydrogenase; Mb: Myoglobin; N%: Neutrophil fraction; PCT: Procalcitonin; PLT: The platelet count; PT: Prothrombin time ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.